The Pharmaceutical Market: Finland

Publisher Name :
Date: 25-Apr-2013
No. of pages: 0
Inquire Before Buying


The macroenvironment for the Finnish pharmaceutical industry is improving. Politically, the new six-party coalition is larger and represents a broader spectrum of opinion than is usual, which could make it unstable. However, the Economist Intelligence Unit (EIU) believes that it will last out its four-year term. Economically, recovery from the downturn is stalling due to the euro area debt crisis. Legally, Finland remains on the USTR's Watch List in 2011 due to concerns over patent protection. Demographically, Finland has one of the largest proportions of population over the age of 65 in Western Europe. Latest projections expect that the population aged 65 and over will constitute more than one-fifth of the total population by 2017. The ageing population means that healthcare is increasingly focused on preventative care.

The Finnish government has introduced several cost-containment measures in recent years in an effort to curb rising healthcare costs. One of the latest affecting the pharmaceutical market in Finland is a reference pricing system. It is hoped that the new system will reduce the use of expensive pharmaceutical products, thus lowering the costs for patients and reducing the pressure to raise health insurance payments. Generic substitution in Finland has been extended to include products with an analogy process patent. As a result, generic substitution will be more effective in terms of saving money, but Finnish manufacturers of patented original products now enter generic price competition several years before product patents expire in other European countries.

There are three leading domestic producers in Finland; Orion, Verman and Vitabalans. Multinational companies Bayer and Santen also have production facilities in Finland. The top ten pharmaceutical companies in Finland had combined sales of over 1.0 billion euros at wholesale prices in 2010, equal to a share of over half of the market. The leading company was Orion, with a market share of nearly 10.0%. This was followed by Pfizer, Novartis, AstraZeneca and GlaxoSmithKline. In the biologic sector, Biotie Therapies completed its acquisition of Synosia Therapeutics in February 2011, while Ark Therapeutics entered into a formal agreement to divest the majority of its woundcare business in the same month.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

The Pharmaceutical Market: Finland

Table Of Contents

  • Increasing New Outlets And Striking Offers To Drive Global Pizza Market
    The global pizza market is predicted to grow at a steady CAGR of about 3% by 2020. Pizza has been gaining massive acceptance globally in the last few years. Consequently, the global pizza market is anticipated to observer considerable progress in the coming years. The growing number of pizzerias is one of the major elements [...]
  • Healthy Diet Demand In Developed Economies To Boost Nutraceuticals
    As customers scuffle to keep up with the frantic lifestyles, the necessity for healthy nutrition rises owing to dearth of time to spend on laborious exercises.  Customers are shifting their attention to swift and healthy food behaviours. Increase in intake of beverages and functional food has offered makers of nutraceuticals with money-spinning prospects to benefit [...]
  • World Economic Forum Unveils Top 10 Emerging Technologies of 2016
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies of 2016. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or [...]
  • Siemens Adds To the Growth of Wind Power Generation Market
    Siemens has been presenting ground-breaking strategies and pioneering solutions for energy generation for an intelligent power supply globally. With an expansive portfolio and wide-ranging proficiency in wind power generation, Siemens is likely to aid in increasing the share of wind power in the US energy mix. With New Mexico’s vicinity to significant wind energy areas, [...]
  • Global Public Safety LTE Ecosystem Overview
    In view of its flourishing ecosystem, spectrum flexibility and performance metrics, LTE has emerged as the leading candidate for public safety mobile broadband networks. Public safety organizations and establishments have already begun planning to advance their networks to LTE-based public safety solutions. LTE provisions a varied range of services, from high bandwidth data services to [...]
  • The Pharmaceutical Market: Ghana
    Published: 08-Jan-2015        Price: US 1295 Onwards        Pages: 122
    Ghana Pharmaceuticals & Healthcare Report We remain of the view that Ghana will be a regional outperformer in terms of the development of its pharmaceutical and healthcare markets over the medium to longer term . On the other hand, reliance on donations and foreign aid to provide some of the medical services and treatments will continue to negatively impact the development of the local drug manufacturing industry. We expect this situation to continue until the government makes substantial......
  • Canada Pharmaceuticals and Healthcare Report Q1 2015
    Published: 10-Dec-2014        Price: US 1295 Onwards        Pages: 112
    BMI View: Canada's epidemiological profile will continue to be attractive to manufacturers of medicines for non-communicable diseases. Despite the relatively rapid uptake of innovative pharmaceuticals, the burden of chronic conditions will increase over the next 15 years. Like many other developed states, Canada is introducing cost-containment measures to restrict the commercial opportunities presented to drugmakers. Headline Expenditure Projections ? Pharmaceuticals: CAD25.6bn (USD24.9bn)......
  • Estonia Pharmaceuticals and Healthcare Report Q1 2015
    Published: 10-Dec-2014        Price: US 1295 Onwards        Pages: 104
    BMI View: Despite growing in recent years, the absolute value of the Estonian pharmaceutical market remains small and will continue to remain a marginal market in the Central and Eastern European region. Low-cost generic drugs are prevalent in the market, with doctors obliged to prescribe by international nonproprietary names (INNs), rather than branded names unless there is a specific medical reason for a branded product to be used. Despite the small size of the pharmaceuticals industry, it......
  • France Pharmaceuticals and Healthcare Report Q1 2015
    Published: 10-Dec-2014        Price: US 1295 Onwards        Pages: 131
    BMI View: Despite the French government partially abandoning fiscal deficit targets in its 2015 budget, cost-containment measures will continue to weigh on the pharmaceuticals and healthcare sector for the foreseeable future. The government's strategy of emphasising preventive care and improved access to doctors will likely avoid long-term costs by reducing the burden or risks associated with unchecked conditions. Meanwhile, it will also sustain access to medicines, including prescription dr......
  • Iran Pharmaceuticals and Healthcare Report Q1 2015
    Published: 10-Dec-2014        Price: US 1295 Onwards        Pages: 117
    BMI View: BMI continues to adjust its forecasts for Iran's pharmaceutical market to account for the sanction-induced currency crisis and high rates of inflation. The rapid depreciation of the rial means that we expect the value of the market to contract sharply in US dollar terms. While improved international relations have reduced the regulatory risk associated with operating in the market for multinational drugmakers, the recent proclamation of the Islamic State (IS) in neighbouring Iraq a......
  • Lebanon Pharmaceuticals and Healthcare Report Q1 2015
    Published: 10-Dec-2014        Price: US 1295 Onwards        Pages: 116
    BMI View: The influx of Syrian refugees into Lebanon is putting a strain on the healthcare system, which is unable to meet the additional demand for treatment. Elevated political instability is putting the pharmaceutical sector at risk in terms of government policy relating to healthcare, while a poor economic outlook is detrimental to the ability to pay for medicine. We expect the continuation of the Syrian civil war to hamper growth in this market. Headline Expenditure Projections ? Phar......
  • Myanmar Pharmaceuticals and Healthcare Report Q1 2015
    Published: 10-Dec-2014        Price: US 1295 Onwards        Pages: 64
    BMI View: Non-governmental organisations will continue to expand healthcare access in Myanmar - a boon for the country's pharmaceutical market. However, the country's poor protection of intellectual property, a weak healthcare system and political instability continues to pose high risks and will restrict company revenue streams. Headline Expenditure Projections ? Pharmaceutical sales: MMK324.8bn (USD350mn) in 2013 to MMK387.5bn (USD390mn) in 2014; +19.3% in local currency terms and +11.3%......
  • Saudi Arabia Pharmaceuticals and Healthcare Report Q1 2015
    Published: 10-Dec-2014        Price: US 1295 Onwards        Pages: 121
    BMI View: We expect heavy investment into Saudi Arabia's healthcare sector to continue, particularly as the government sees the sector as key to the diversification of the economy. The medical tourism industry in particular provides opportunities for both pharmaceutical and medical device companies. We expect multinational companies will continue to dominate the local market despite stringent regulatory laws. Headline Expenditure Projections ? Pharmaceuticals: SAR24.65bn (USD6.58bn) in 2013......
  • Sudan Pharmaceuticals and Healthcare Report Q1 2015
    Published: 10-Dec-2014        Price: US 1295 Onwards        Pages: 59
    BMI View: The already depreciating Sudanese pound will come under further strain should oil prices continue their decline as oil exports account for around 70% of total exports in the country. We are already forecasting short-term negative growth in US dollar terms for the pharmaceutical market which could come under increased scrutiny should prices decline further. Our long-term outlook is more positive due to the government's plans to develop the pharmaceutical sector and expand access to ......
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs